검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Biologics |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Spondyloarthritis (SpA) |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting bone-remodeling pathway |
MoA Biomarker | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human, In vitro |
Toxicology Major finding | Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis.. Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility and recurrent fractures. Emerging biologics demonstrate promise by targeting bone-remodeling pathways, yet evidence for their efficacy and safety rema… |
Clinical Primary efficacy | ORR 11.11% |
Clinical ORR | 11.11% |
Clinical Result source | ClinicalTrials.gov NCT04458922 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Biologics |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Spondyloarthritis (SpA) |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting bone-remodeling pathway |
MoA Biomarker | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human, In vitro |
Toxicology Major finding | Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis.. Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility and recurrent fractures. Emerging biologics demonstrate promise by targeting bone-remodeling pathways, yet evidence for their efficacy and safety rema… |
Clinical Primary efficacy | ORR 11.11% |
Clinical ORR | 11.11% |
Clinical Result source | ClinicalTrials.gov NCT04458922 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교